Tempus AI 3Q 2026: Revenue $411.5M, Net loss $14.9M — 10-Q Summary

What happened

Tempus AI reported third-quarter 2026 revenue of $411.5M, up 23% from a year earlier, and a net loss of $14.9M, compared with an $80M loss. Adjusted EBITDA, a measure of operating performance, was $25.6M. Diagnostics test volume and Data and applications revenue also grew.

Confirmed

Global impact / market context

Higher revenue and a narrower reported loss may indicate improving business scale, while positive adjusted EBITDA suggests stronger operating performance on that measure. Continued investment in tests, algorithms, technology, and new disease areas could raise costs before generating additional revenue, making future growth and cash use important.

Analyst inference

The results point to growth across both diagnostics testing and data products, rather than reliance on only one business line. Data and applications revenue rose 33%, while test volume increased; investors may weigh that expansion against the remaining net loss and planned investment needs.

Analyst inference

What to watch

1. Check whether revenue growth and the narrower net loss continue in later reported quarters, since sustained improvement would strengthen evidence that the business is scaling. Analyst inference
2. Watch whether planned investment in assays, algorithms, technology, and new disease areas is carried out; the article says Tempus plans continued investment. Confirmed
3. Track whether Data and applications revenue and diagnostic test volumes keep growing, as continued adoption could support sales while adding operating demands. Analyst inference

Evidence

• Original source link unavailable